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Introduction: Hemorrhagic transformation (HT) is a complication of reperfusion therapy
for acute ischemic stroke. Blood–brain barrier (BBB) disruption is a crucial step toward
HT; however, in clinical studies, there is still uncertainty about this relation. Hence, we
conducted a systematic review and meta-analysis to summarize the current evidence.
Methods: We performed systematic review and meta-analysis of observational studies
from January 1990 to March 2020 about the relation between BBB disruption and HT in
patients with acute ischemic stroke with both computed tomography (CT) and magnetic
resonance (MR) assessment of BBB. The outcome of interest was HT at follow-up
imaging evaluation (within 48 h from symptom onset). We pooled data from available
univariate odds ratios (ORs) in random-effects models with DerSimonian–Laird weights
and extracted cumulative ORs.
Results: We included 30 eligible studies (14 with CT and 16 with MR), N = 2,609
patients, with 88% and 70% of patients included in CT and MR studies treated with
acute stroke therapy, respectively. The majority of studies were retrospective and had
high or unclear risk of bias. BBB disruption was measured with consistent methodology
in CT studies, whereas in MR studies, there was more variability. All CT studies provided
a BBB disruption cutoff predictive of HT. Four CT and 10 MR studies were included in the
quantitative analysis. We found that BBB disruption was associated with HT with both
CT (OR = 3.42; 95%CI = 1.62–7.23) and MR (OR = 9.34; 95%CI = 3.16–27.59). There
was a likely publication bias particularly for MR studies.
Conclusion: Our results confirm that BBB disruption is associated with HT in both
CT and MR studies. Compared with MR, CT has been more uniformly applied in the
literature and has resulted in more consistent results. However, more efforts are needed
for harmonization of protocols and methodology for implementation of BBB disruption
as a neuroradiological marker in clinical practice.
Keywords: blood-brain-barrier, ischemic stroke, hemorrhagic transformation (HT), perfusion tomography,
magnetic resoance imaging, intravenous thrombolysis, endovascular treatment (EVT)
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INTRODUCTION
Ischemic stroke is a major cause of death and disability all
over the world. In the last decades, acute treatments aiming to
recanalize the occluded vessel demonstrated efficacy in reducing
the functional burden of the disease; however, reperfusion of
the ischemic tissue brings some risk, with the most feared
being hemorrhagic transformation (HT). HT is a common
phenomenon after brain ischemia, occurs in up to 40% of patients
treated with acute stroke therapy (1), and is fatal in around 3% of
patients (2). Identification of factors predictive of HT is therefore
important to stratify the hemorrhagic risk of patients and for
management of the hyperacute stroke phase.
In vitro and in vivo models suggested failure of endothelial
integrity and loss of neurovascular homeostasis as the cellular
mechanisms underlying blood extravasation (3, 4) and, from a
structural point of view, disruption of the blood–brain barrier
(BBB) as the pathophysiological step that leads to HT (5, 6). In
vivo visualization and measurement of BBB disruption in the
acute stroke setting before reperfusion therapy may represent
a useful marker to identify patients more prone to develop
HT. BBB disruption can be evaluated with either computed
tomography (CT) or magnetic resonance (MR). Within each
imaging technique, BBB disruption can be investigated using
different algorithms that mainly measure contrast extravasation
through microcirculation, with either qualitative or quantitative
methods (7).
Although diverse studies have provided data about the link
between BBB disruption and HT, no conclusive evidence is
available, and BBB disruption, although potentially a useful
biomarker, has not yet been adopted in clinical practice with
regard to acute ischemic stroke. To investigate the effect of BBB
disruption on HT and provide more precise estimate of this
effect, we performed a systematic review of studies that evaluated
BBB disruption with either CT or MR in acute ischemic stroke
setting and subsequent HT.
METHODS
This review was performed according to Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) (8)
and Meta-analysis Of Observational Studies in Epidemiology
(MOOSE) (9) recommendations and the Cochrane Handbook
for Systematic Review of Interventions (https://training.
cochrane.org/handbook). Data search, extraction, analysis,
and interpretation were performed following a pre-specified
study protocol developed by the investigators (not registered
or published).
Search Strategy and Selection Criteria
Potentially eligible studies were identified using PubMed
and EMBASE databases by two independent investigators
(FA and CR). Discrepancies were solved by consensus
of all authors. We searched for eligible published studies
in English, from January 1990 to March 2020, using the
following search strategy: (“acute ischemic stroke” OR
((stroke OR “Acute Cerebrovascular Accident” OR “Acute
Cerebrovascular Accidents”) AND (ischaemic OR ischemic)))
AND ((hemorrhag∗ OR haemorrhag∗ OR “parenchymal
hematoma” OR “Cerebral Hemorrhage”[Mesh]) AND
(Transform∗ OR Petechia∗ OR subsequent OR infarct∗))
AND (“computed tomography perfusion” OR “CT perfusion”
OR “perfusion computed tomography” OR “perfusion CT” OR
“computed tomographic perfusion” OR ((“Perfusion”[Mesh] OR
“Perfusion Imaging”[MeSH Terms])AND “Tomography, X-Ray
Computed”[Mesh])) for CT studies in PubMed; (“acute ischemic
stroke” OR ((stroke OR “Acute Cerebrovascular Accident”
OR “Acute Cerebrovascular Accidents”) AND (ischaemic
OR ischemic))) AND ((hemorrhag∗ OR haemorrhag∗ OR
“parenchymal hematoma” OR “Cerebral Hemorrhage”[Mesh])
AND (Transform∗ OR Petechia∗ OR subsequent OR infarct∗))
AND ((“Magnetic Resonance Imaging”[Mesh] OR “NMR
Imaging” OR “MR Tomography” OR “NMR Tomography” OR
“Steady State Free Precession MRI” OR Zeugmatography OR
“Proton Spin Tomography” OR “MRI Scans” OR “MRI Scan” OR
“Spin Echo Imaging” OR “magnetization transfer” OR “magnetic
resonance imaging” OR “magnetic resonance tomography”
OR “mr imaging” OR MRI OR “magnetic resonance”) AND
(permeability OR “blood-brain-barrier” OR BBB)).
The reference list of eligible studies was screened to identify
additional publications suitable for our purposes not included in
the original list. We applied the following inclusion criteria: (1)
English-written articles; (2) patients with acute ischemic stroke;
(3) studies with observational (retrospective or prospective)
design; (4) patients treated or not with acute stroke therapy (i.e.,
intravenous thrombolysis, intra-arterial procedures, or both); (5)
assessment of BBB disruption with CT or MR scan before any
acute stroke treatment; (6) assessment of HT at the follow-up
CT or MR scan within 48 h from the first scan; and (7) studies
with more than 10 patients. Case reports, conference abstracts,
study protocols, and unpublished studies were not included. We
also excluded experimental or animal studies. Where studies
had overlapping cohorts, only the study with the largest sample
size was included. We included studies that evaluated BBB
disruption as either continuous or categorical (dichotomized)
variable. Assessment of BBB disruption was defined either as
quantitative when a numerical value within a continuous scale
was provided or as qualitative when a visual rating (e.g., presence
vs. absence of contrast parenchymal enhancement) was provided.
Localization of BBB disruption was defined as follows: “focal”
when the BBB disruption was detected and measured only in a
restricted area of the whole ischemic tissue and “global” when
the BBB disruption was detected and measured in the whole
ischemic tissue.
Risk of Bias Assessment
Three investigators (CR, DC, and FV) independently extracted
data from relevant studies using a predefined form including the
following sections: (1) year of publication and study period; (2)
study design; (3) inclusion and exclusion criteria; (4) clinical and
radiological data; (5) definition and measurement of BBB; and
(6) definition of HT. The same three investigators assessed study
quality and risk of bias using the Newcastle-Ottawa Scale for
cohort studies and the Cochrane “Tool to Assess Risk of Bias
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in Cohort Studies” (https://methods.cochrane.org/). In case of
uncertainty, the final decision was taken by an expert (FA).
Outcome
Our main outcome of interest was HT evaluated with CT or
MR scan within 48 h from the first scan. We included studies
with the following definitions of HT: (1) presence/absence; (2)
ECASS-2 (European Co-operative Acute Stroke Study-II) (3)
(10) NINDS (National Institute of Neurological Disorders and
Stroke) (11) criteria; and (4) SITS-MOST (Safe Implementation
of Thrombolysis in Stroke: Monitoring Study) (12) criteria.
Statistical Analysis
Data were pooled in the meta-analysis when at least two studies
had available data on the main outcome of interest, i.e., HT. In
all analyses, we used a random-effects model with DerSimonian–
Laird weights. The direction and strength of the association
between BBB permeability and HT were quantified using crude
(i.e., unadjusted) odds ratio (OR) and their corresponding 95%
confidence intervals (CIs), with the inverse variance method for
weighting. We therefore included in the quantitative analysis
(i.e., meta-analysis) only studies with available unadjusted OR.
Statistical heterogeneity was assessed with I2 statistics and visual
inspection of forest plots. Values of ≤25, 25 to 50, and ≥50%
were defined as low, moderate, and high degrees of heterogeneity,
respectively. Publication bias was explored on funnel plots. All
the analyses were performed inMay 2020 using the meta-analysis
software RevMan 5 (https://community.cochrane.org/).
Data Availability
Requests to access the dataset from qualified researchers trained
in human subject confidentiality protocols may be sent to the
corresponding author.
RESULTS
The initial search retrieved 656 results. After removing 189
duplicates, we screened 467 titles and abstracts and excluded
434 articles. We therefore examined 33 full-text articles and
excluded two studies for sample size <10 patients, one study
for overlapping cohort, two studies for an inadequate follow-
up rate, and one study for missing HT assessment. We retrieved
three studies from reference snowballing; we therefore included
in the systematic review 30 articles. Of these, 14 had BBB
assessment with CT (13–26) and 16 with MR (27–42), with
a total of 2,609 patients (1,510 with CT and 1,099 with MR).
The study selection process is illustrated in Figure 1. Data for
the quantitative analysis (meta-analysis) were available for 1,298
(50%) patients, from 4/14 studies with CT (794 patients, 53%
of patients included in CT studies) and 9/16 MR studies (504
patients, 45% of patients included in MR studies). Clinical data
of studies included in the meta-analysis are shown in Table 1.
Computed Tomography Studies
Five studies were found as having a low risk of bias
(15, 21, 23, 24, 26), seven a high risk (13, 17–20, 22, 25),
and two an unclear risk (14, 16) (Supplemental Table 1). The
general clinical characteristics of the included studies evaluating
BBB with CT are summarized in the Supplemental Table 2.
Studies were performed between 2004 and 2020; were from
Europe (5), Asia (5), and North America (4); and were mainly
single-center clinical cohorts, and five were with prospective
design. Four studies had a sample size larger than 100 patients.
Among 1,510 patients, a total of 359 (24%) had HT of any
grade. The great majority of included patients (1,328/1,510; 88%)
were treated with acute stroke therapy, including intravenous
thrombolysis (N = 921), mechanical thrombectomy (N =
145), both (N = 58), and intra-arterial procedures (other than
mechanical thrombectomy, N = 204); 150 (10%) patients
received no treatment. For 32 (2%) patients, treatment type
was not available. BBB assessment was performed within 24 h
from symptom onset in all included studies. BBB disruption was
measured with quantitative models in all studies: five studies
used Ktrans, eight studies permeability surface (PS) products,
and one study both parameters. Seven studies assessed focal
BBB disruption, two studies global BBB disruption, and three
studies both; in two studies, the localization of BBB assessment
was not available. The radiological characteristics of the included
studies are shown in Supplemental Table 3. Vendor largely
varied across and within studies, slice number of scan acquisition
ranged from 40 to 320, coverage ranged from 2.4 to 9 cm (five
studies did not provide coverage), images were obtained with
single-phase acquisition protocols in 10 studies and with a
two-phase acquisition protocol in three studies, and acquisition
time ranged across studies from 40 to 1,092 s. All CT studies
performed a quantitative BBB disruption evaluation, which was
made with the Patlak model in seven studies, with the non-
linear-regression model in two studies and the Johnson–Wilson
model in two studies, whereas in two studies, the model was
not stated. Eleven studies provided a cutoff of BBB disruption
predictive of HT (Supplemental Table 3), which ranged from
0.33 to 7 ml/100 mg/min in studies with Ktrans and from 0.23 to
6 ml/100 mg/min in studies with PS.
Univariate ORs were present in four studies (N = 794)—two
prospective (24, 26) and two retrospective (15, 23)—other studies
provided only multivariate or did not provide ORs. In the meta-
analysis of the four aforementioned studies, BBB disruption was
associated with HT (OR = 3.42; 95%CI = 1.62–7.23). We found
moderate statistical heterogeneity across studies (I2 = 51%; p
= 0.001) (Figure 2). Visual inspection of funnel plots showed
slight asymmetry, suggesting possible presence of publication
bias Supplemental Figure 1; we did not perform further tests to
explore publication bias since we pooled <10 studies.
Magnetic Resonance Studies
Five studies were found as having a low risk of bias (27, 38, 39,
41, 42), eight a high risk (28–31, 33, 34, 37, 40), and three an
unclear risk (32, 35, 36) (Supplemental Table 4). The general
clinical characteristics of the included studies evaluating BBB
with MR are summarized in the Supplemental Table 5. Studies
were performed between 1997 and 2018 and were from North
America (7), Europe (4), Asia (2), or international cohorts (2) and
were mainly single-center clinical cohorts; all but one are with
retrospective design. Three studies had a sample size larger than
Frontiers in Neurology | www.frontiersin.org 3 January 2021 | Volume 11 | Article 594613
Arba et al. Blood-Brain-Barrier and Hemorrhagic Transformation
FIGURE 1 | Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flowchart of study selection.
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FIGURE 2 | Relation between BBB and HT in CT studies. BBB, blood–brain barrier; HT, hemorrhagic transformation; CT, computed tomography.
FIGURE 3 | Relation between BBB and HT in MR studies. BBB, blood–brain barrier; HT, hemorrhagic transformation; MR, magnetic resonance.
100 patients. Among 1,099 patients, a total of 326 (29.7%) hadHT
of any grade. The majority of included patients (759/1099; 69%)
were treated with acute stroke therapy, including intravenous
thrombolysis (N = 502), mechanical thrombectomy (N = 146),
both (N = 109), and intra-arterial procedures (not specified,
N = 2); 340 (31%) patients received no acute treatment. In
nine studies, BBB assessment was performed within 24 h from
symptom onset, whereas in seven studies, information about
time of BBB assessment was not available. Twelve studies
assessed focal, and four studies global BBB disruption. The
radiological characteristics of the included studies are shown in
the Supplemental Table 6. Compared with CT studies, there was
less variability in vendor type, but three studies did not state the
vendor type. Imaging studies were performed mainly on 1.5-T
scanners; in two studies, magnetic field was not available. Section
thickness was 5mm in the majority of studies, although it was
not specified in five studies; acquisition time ranged from more
than 60 s to nearly 5min and was not stated in 10 studies. Six
studies measured BBB disruption with qualitative parameters
such as parenchymal enhancement or extravasation of contrast,
whereas seven studies provided quantitative measurements of
BBB disruption. Of the latter studies, two studies used the Patlak
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model, and five studies used first-pass T2∗ method. Only four
studies, using different BBB measurements, provided a BBB
disruption cutoff predictive of HT.
Univariate ORs were present in 10 studies (N = 609)—
one was prospective (30), nine were retrospective (27–29,
32–36, 39, 42), and three studies provided quantitative (N
= 209) and seven qualitative (N = 400) BBB disruption
assessment. Other studies provided only multivariate or did
not provide OR. In the meta-analysis, BBB disruption was
associated with HT (OR= 9.34; 95%CI= 3.16–27.59) (Figure 3).
We found high statistical heterogeneity across studies (I2 =
72%; p < 0.00001). The association between BBB disruption
and HT was confirmed in the sensitivity analysis for studies
with qualitative assessment of BBB (OR = 9.96; 95%CI =
2.82–35.20; Supplemental Figure 2), whereas the association
was not confirmed for studies with quantitative assessment
(OR = 9.33; 95%CI = 0.76–114.39; Supplemental Figure 3).
Visual inspection of funnel plots showed asymmetry suggesting
presence of publication bias (Supplemental Figure 4); we did not
perform further tests to explore publication bias since we pooled
10 studies.
DISCUSSION
In this systematic review, we brought together available
observational studies regarding the relation between BBB
disruption and HT in acute ischemic stroke patients. Overall,
our results confirmed the association between BBB disruption
and HT. While CT studies showed a three-fold increased risk
of HT, MR studies showed a nine-fold increased risk of HT,
with around six-fold increased difference in MR studies. Among
studies included in the meta-analysis, only three (36, 39, 42)
out of 10 MR studies had quantitative assessment of BBB
disruption; MR studies had smaller sample size compared with
CT studies, as reflected by the wider confidence intervals in the
pooled MR analysis. Furthermore, in the sensitivity analysis for
MR, quantitative BBB disruption was not associated with HT,
whereas the association was confirmed in qualitative studies. It is
important to note that the majority of the included studies were
retrospective, with a high risk of bias and a likely publication bias;
thus, our conclusions have limitations.
We found more MR studies with assessment of BBB, and
the rate of HT was higher in MR studies, perhaps alluding to
the higher sensitivity of MR in diagnosis of HT. By contrast,
the pool of patients included in studies with CT was larger, and
methodology and protocols were generally more consistent with
each other. Patients enrolled in CT studies were more frequently
treated with acute stroke therapy than those enrolled in MR
studies. Given that acute stroke treatment increases the odds
of HT occurrence, the results from CT studies mainly apply to
patients treated with acute stroke therapy. Conversely, results
from MR studies, although more generalizable to all ischemic
stroke patients, included more heterogeneity with regard to
treatment, with around a third of patients not treated with
acute stroke treatment. While all CT studies provided a time
frame for the study inclusion, around a half of MR had missing
information about the time from onset of stroke to enrollment
in the study. This is an important limitation, because extent of
BBB disruption is thought to be time-dependent (43–45), and
the timing of BBB assessment is therefore a pivotal information.
Finally, occlusion site is fundamental for stroke therapy, since
endovascular therapy proved efficacy only in anterior circulation
(46), whereas in the posterior circulation, there is no conclusive
evidence (47). Evaluation of BBB disruption may be challenging
with CT in the posterior circulation due to the limits of perfusion
technique in this area (48), whereas it is feasible with MR with
dynamic contrast-enhanced sequences. However, the majority of
CT studies enrolled patients with ischemic stroke in the anterior
circulation, whereas the site of occlusion was not stated in many
MR studies. As confirmation of the methodological variability
of MR studies, we found a high statistical heterogeneity for
MR studies compared with moderate heterogeneity for CT
studies. Although we acknowledge that the precision of MR in
detecting BBB disruption and HT is likely superior to CT, all
those methodological pitfalls of MR studies limit considerably
direct transferability of results into clinical practice.
There are diverse methods for evaluation of BBB disruption.
BBB was measured with Ktrans or PS in CT studies, whereas
MR studies adopted qualitative and quantitative methods,
although some study did not specify how BBB was measured.
Remarkably, all CT studies provided quantitative measurements
with continuous values for BBB disruption, whereas around
a half of MR studies provided qualitative evaluation of BBB,
i.e., presence/absence of contrast leakage. BBB disruption is a
dynamic process that varies with age, vascular risk factors such as
diabetes and hypertension, and pre-existing characteristics of the
brain (49, 50). Some degree of BBB disruption may be present
up to 95% of patients with acute stroke within the ischemic
area (51); thus, quantitative measurement of BBB disruption
is useful to provide a precise estimate of HT risk. In order to
differentiate pathologic from physiologic BBB leakage, it is also
important to identify a cutoff value predictive of HT, since
qualitative assessment of BBB disruption (i.e., presence/absence),
although easily detectable, may not provide enough information
to accurately estimate risk of subsequent HT. However, we
observed a large inconsistency among cutoffs provided among
diverse studies. Two meta-analyses were attempted to provide
diagnostic accuracy of CT parameters, including BBB disruption,
in predicting HT (52, 53). Although both studies found that BBB
disruption has good sensitivity and specificity for HT prediction,
there was high heterogeneity across studies due to several
reasons, particularly differences in protocols and methods of CT
perfusion for BBB evaluation. This is in keeping with our results
that confirmed moderate and high statistical heterogeneity for
CT andMR studies, respectively, and showed relevant differences
across studies in qualitative analysis, highlighting the need of
standardized and replicable protocols for BBB assessment in
clinical setting.
Evaluation of BBB disruption may help in early stratification
of hemorrhagic risk in patients with ischemic stroke, particularly
those treated with intravenous thrombolysis and/or endovascular
procedures (5, 40). HT extent may range from single-blood
petechiae with few clinical consequences to symptomatic HT
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with a high rate of mortality and disability. While most studies
reported the association between BBB disruption and HT, only
few studies investigated the relation with unfavorable outcomes
such as symptomatic intracranial hemorrhage (sICH) (20, 26,
34); therefore, this association, although potentially useful for
clinicians, is still unclear and needs to be further clarified.
Our study has limitations that need to be addressed. Our
quantitative analysis is based on unadjusted pooled estimates,
and therefore, the association was not adjusted for other
covariates and predictors of HT, such as age, stroke severity, and
time from symptom onset to imaging. However, we extracted
from the studies mean age of patients, stroke severity, site of
occlusion, and time from onset to enrolment, and we observed
that particularly in CT studies, such variables were similar,
whereas in MR studies, there was more difference. It should
be noted that only 4/14 CT studies (15, 23, 24, 26) and
10/16 MR studies (27–30, 32, 34–36, 42) reported univariate
associations between BBB disruption and HT and were included
in the meta-analysis; consequently, the ORs were found to
represent a gross estimate of the relation between BBB and
HT and should be interpreted with caution. Many CT and MR
studies reported only adjusted associations; however, the sets of
covariates largely differed across studies; thus, pooling-adjusted
ORs were potentially inappropriate. This was also reflected by the
number of studies with high or unclear risk of bias, mainly due to
the adjusted analysis that often included covariates not relevant
for the outcome of interest. Furthermore, funnel plots of studies
included in the quantitative analysis suggested the presence of
publication bias particularly forMR studies, possibly inflating the
magnitude of effect of the association between BBB disruption
and HT. Again, we examined studies from 1990 to 2020, and
this may be a limitation due to the evolution in methods and
technology for imaging in such a large time span. However,
with a 30-year period of evaluation, our qualitative analysis is
a comprehensive synthesis of available studies relevant for the
topic, and the quantitative analysis attempted to provide ORs
useful for future research. As a further limitation, we included
only English-written studies.
More data are needed to overcome the limitations of current
evidence about BBB disruption and HT. Our results suggest
that protocols for BBB assessment need to increase consistency,
BBB disruption evaluation should be quantitative, and future
studies should provide a cutoff predictive of HT, preferably
sICH or relevant HT. Furthermore, methodology and workflow
of the studies should be easily reproducible and accessible.
In this regard, as previously suggested (54, 55), CT seems
to represent a fair trade-off between diagnostic detail and
feasibility in acute stroke setting due to availability and few
contraindications; however, MR is likely more accurate in
detection of both BBB disruption and HT. Use of machine
learning algorithms for MR (56) may help standardization of
acquisition protocols and assessment of BBB in acute stroke;
however, there is still no available evidence in this regard.
Our results from the meta-analysis show that the association
between BBB and HT is confirmed with both CT and MR,
although with relevant limitations. Results from the systematic
review suggest ease of standardized acquisition protocols, similar
methodology, and similar characteristics of study population,
which are the strengths of CT studies over MR, whereas the
lack of standardized measurements for BBB disruption and
quantitative cutoffs predictive of HT are the pitfalls of both CT
studies andMR studies. Future studies need to define feasibility of
protocols for BBB assessment and whether BBB disruption may
serve as an adjunctive marker to identify patients at risk of HT,
thus helping decision making andmanagement of acute ischemic
stroke patients.
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